Protagonist Therapeutics (PTGX) reported Q4 earnings Friday of $1.98 per diluted share, up from $0.44 a year earlier.
License and collaboration revenue for the quarter ended Dec. 31 was $170.6 million, compared with $60 million a year earlier.
The company said it expects its cash, cash equivalents and marketable securities of $559.2 million as of Dec. 31 to provide cash runway through the end of 2028.
Shares of the company were up more than 4% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。